TY - JOUR
T1 - Adjuvant therapy for renal cell carcinoma, finally a new standard?
AU - Renner, Alex
AU - Rojas, Carlos
AU - Walton-Diaz, Annerleim
AU - Burotto, Mauricio
N1 - Publisher Copyright:
Copyright © 2022 Renner, Rojas, Walton-Diaz and Burotto.
PY - 2022/9/29
Y1 - 2022/9/29
N2 - Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results with immune checkpoint inhibitors may change the current standard, and several ongoing trials are exploring new alternatives. In this perspective, we aim to provide an overview of previous adjuvant therapy efforts, current data supporting the use of checkpoint blockade, and a future outlook for adjuvant therapy in renal cell carcinoma.
AB - Localized renal cell carcinoma (RCC) has the potential to be cured with surgery alone; however, some patients have a high risk of relapse and may benefit from additional treatment. Several efforts have been made to identify effective strategies, with mostly negative results. However, recent results with immune checkpoint inhibitors may change the current standard, and several ongoing trials are exploring new alternatives. In this perspective, we aim to provide an overview of previous adjuvant therapy efforts, current data supporting the use of checkpoint blockade, and a future outlook for adjuvant therapy in renal cell carcinoma.
KW - adjuvant
KW - immunotherapy
KW - pembrolizumab
KW - renal cell carcinoma
KW - tyrosine kinase inhibitions (TKIs) therapy
UR - http://www.scopus.com/inward/record.url?scp=85148365284&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.926661
DO - 10.3389/fonc.2022.926661
M3 - Article
AN - SCOPUS:85148365284
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 926661
ER -